The latest in a long line of HDL-raisers fails to benefit patients. Will more potent pills do the trick?
Matthew Herper, Forbes
Mon, 05/07/2012 - 5:07am
The latest in a long line of HDL-raisers fails to benefit patients. Will more potent pills do the trick?